PRTA | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 30%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.89%

1 Month

18.08%

3 Months

-10.93%

6 Months

15.32%

1 Year

-34.05%

2 Year

-65.22%

Key data

Stock price

$9.86

P/E Ratio

0.00

DAY RANGE

$9.36 - $9.96

EPS

-$5.21

52 WEEK RANGE

$4.32 - $15.63

52 WEEK CHANGE

-$34.83

MARKET CAP

525.381 M

YIELD

N/A

SHARES OUTSTANDING

53.830 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$511,214

AVERAGE 30 VOLUME

$445,619

Company detail

CEO: Gene G. Kinney
Region: US
Website: prothena.com
Employees: 130
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.

PRTA - PROTHENA CORP PUBLIC LTD CO